



RR/MDR-TB cases: estimated, reported, and under treatment. The Americas, 2016-2018



Proportion of DST performed in new and previously treated TB cases. The Americas, 2013 - 2018



Globally (2018)

- 484,000 new cases of RR/MDR-TB* were estimated and about 214,000 deaths were due to RR/MDR-TB. The number of people enrolled in treatment was 156,071 (32%).
- The three countries with the largest share of the global burden were India (27%), China (14%) and the Russian Federation (9%).
- 3.4% of new TB cases and 18% of previously treated cases had RR/MDR-TB.
- The success rate was 56% for RR/MDR-TB, 15% died, 15% were lost to follow-up and for 6% there was no outcome information (2016).
- As part of the efforts to improve the treatment outcomes for patients with MDR/XDR-TB, the countries have introduced the use of new drugs: 90 are using bedaquiline and 57 delamanid.

In the Americas (2018):

- There were an estimated 11,000 cases of RR/MDR-TB, and 4,791 (44% of the estimate) were diagnosed.
- 90% of the estimated cases of RR/MDR-TB are found in 10 countries of the Region. Peru represented 22% and Brazil 23% of all MDR-TB estimated cases in the region.
- Of the 4,791 cases of RR/MDR-TB diagnosed, 88% began treatment.
- DST** coverage is low. It was performed only in 34% of new cases and 46% of previously treated cases.
- 150 cases of XDR-TB*** were diagnosed and reported by 9 countries in the Region. Peru reported 98 XDR-TB cases and Brazil 26.

* RR/MDR-TB : rifampicin-resistant/multidrug-resistant (resistant to at least isoniazid and rifampicin) tuberculosis. **Drug susceptibility testing.
*** XDR-TB: MDR-TB + resistance to any fluoroquinolone and at least one of the three second-line injectable.

Diagnosis of RR/MDR/XDR-TB

- 140 laboratories in the Region perform phenotypic DST for first-line drugs and 55 for second-line drugs
- 29 laboratories perform LPA* for rifampicin and isoniazid and 16 of them for second-line drugs
- 491 laboratories perform the Xpert MTB/RIF assay**



Treatment of RR/MDR/XDR-TB

- 2,666 patients with RR/MDR-TB started treatment in 2016. The treatment success rate (59%) is negatively affected by the high proportion of lost to follow-up patients (25%).
- The treatment success among XDR-TB patients were 62%, higher than the MDR-TB. The death were 15% and lost to follow-up were 13%.
- The outcomes in cohorts evaluated show that patient-centered care aimed at boosting treatment adherence must be strengthened.

* LPA: system of nucleic acid amplification and hybridization on strips with immobilized probes

** Xpert MTB/RIF: Molecular test based on real-time PCR in a closed cartridge

Treatment outcomes in RR/MDR-TB and XDR-TB. The Americas 2014-2016

